Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In Phase 3 trials, it demonstrated substantial weight loss and improved glycemic control in patients with type 2 diabetes
Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, et al
Unlike BCTC, exendin 939 also mitigated both thermal and mechanical nociceptive behaviors in mice without inducing hyperthermia, indicating that it is a viable analgesic without the common adverse effects associated with existing pain management strategies, such as opioids and traditional TRPV1 antagonists 32,42,51,52,53
2019;9:e01375
US$ 26.84
US$ 22.98
US$ 21.78
US$ 28.03
US$ 21.20
US$ 23.95
US$ 27.44
